Two female scientists dedicated to developing new advancements in medicine.
A group of young adults practicing yoga outside, feeling confident, connected and healthy.
A male and female scientist examine a test tube to asses a breakthrough that could transform current treatment paradigms.
A middle-aged woman and her young daughter happily spending time together outside.
Two female scientists dedicated to creating a breakthrough treatment that could change the lives of patients.
A young father laughs with joy as he plays with his ballerina daughter and lifts her high into the air.
A three-dimensional rendering of a monoclonal antibody (mAb).
EPTINEZUMAB

Our pivotal-stage monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP), and is currently in late-stage clinical development for the prevention of migraine.

LEARN MORE

A tablet on a stack of newspapers displaying the Alder BioPharmaceuticals website.
LATEST NEWS

Alder BioPharmaceuticals® Presents New Data on Migraine-Free Months, Migraine Severity and Quality of Life, Demonstrating Eptinezumab’s Clinical Profile for Migraine Prevention

            - Posters presented at the 2019 American Headache Society meeting highlight eptinezumab’s safety profile and suppression of... LEARN MORE

The U.S. Food and Drug Administration (FDA) accepted Alder’s Biologics License Application for eptinezumab in April 2019, with a Prescription Drug User Fee Act (PDUFA) target action date of February 21, 2020.

CONTACT US General inquiries:
Click here

ADDRESS & PHONE / FAX Corporate Headquarters
Alder BioPharmaceuticals, Inc.
11804 North Creek Parkway South
Bothell, WA 98011

Phone: 425-205-2900
Fax: 425-205-2901